Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Calorie restriction extends lifespan and produces a metabolic profile desirable for treating diseases of ageing such as type 2 diabetes. SIRT1, an NAD+-dependent deacetylase, is a principal modulator of pathways downstream of calorie restriction that produce beneficial effects on glucose homeostasis and insulin sensitivity. Resveratrol, a polyphenolic SIRT1 activator, mimics the anti-ageing effects of calorie restriction in lower organisms and in mice fed a high-fat diet ameliorates insulin resistance, increases mitochondrial content, and prolongs survival. Here we describe the identification and characterization of small molecule activators of SIRT1 that are structurally unrelated to, and 1,000-fold more potent than, resveratrol. These compounds bind to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. In diet-induced obese and genetically obese mice, these compounds improve insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. In Zucker fa/fa rats, hyperinsulinaemic-euglycaemic clamp studies demonstrate that SIRT1 activators improve whole-body glucose homeostasis and insulin sensitivity in adipose tissue, skeletal muscle and liver. Thus, SIRT1 activation is a promising new therapeutic approach for treating diseases of ageing such as type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, we show that recently developed SIRT1 activators, which are effective in improving energy homeostasis and decreasing hepatosteatosis in mouse models (Milne et al. 2007;Feige et al. 2008), also increase ubiquitination and proteasomal targeting of SREBP-1a, resulting in decreased SREBP-1 nuclear levels and target gene expression.”
From Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP (2010) · cites this paper as Milne et al. 2007
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have reported the identification of potent SIRT1-activating compounds, and showed that such SIRT1 activators could significantly ameliorate insulin resistance and improve energy homeostasis in mouse diet-induced obesity models (Milne et al. 2007).”
From Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP (2010) · cites this paper as Milne et al. 2007
In the citing paper
“In contrast to these negative regulators of insulin action, SIRT1 appears to be a positive regulator of insulin sensitivity (43,44).”
From Insulin sensitivity: Modulation by nutrients and inflammation (2008) · cites this paper as [43]
In the citing paper
“Additionally, the non-naturally occurring sirtuin-activating compound, SRT1720, has enhanced insulin sensitivity and oxidative metabolism in animal models of obesity, in part, by improving mitochondrial oxidative capacity231.”
From Mitochondrial and metabolic dysfunction in ageing and age-related diseases (2022) · cites this paper as [231]
In the citing paper
“Other related small molecules are more potent than resveratrol to enhance the action of SIRT1 on substrates for deacetylation (218). These compounds also improve insulin sensitivity in obese rodents (218).”
From Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities (2010) · cites this paper as [218]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Self-citationLagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Self-citationSmall molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796
Self-citationTranscriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Kaeberlein, M., McVey, M., & Guarente, L. (1999) · Genes & Development · doi:10.1101/gad.13.19.2570 · Cited by 2,253
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase
Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., Kessler, B., Howitz, K. T., Gorospe, M., de Cabo, R., & Sinclair, D. A. (2004) · Science · doi:10.1126/science.1099196 · Cited by 1,924
Self-citationSirtuin activators mimic caloric restriction and delay ageing in metazoans
Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., & Sinclair, D. (2004) · Nature · doi:10.1038/nature02789 · Cited by 1,868
Self-citation
Research works printed but not linked: 1
- Banks A, et al. Overexpression of the Sirtuin SIRT1 increases insulin sensitivity in aging mice. Diabetes. 2007;56(S1):0234-OR. [Google Scholar]
Cited by
Items 301–400 of 1,004
A continuous microplate assay for sirtuins and nicotinamide-producing enzymes
Smith, B. C., Hallows, W. C., & Denu, J. M. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.07.019 · Cited by 137
“Although several other sirtuin high-throughput screens have been reported [8,12,14,19,36], the coupled assay could be adapted to a high-throughput format.”
BackgroundSIRT1/eNOS Axis as a Potential Target against Vascular Senescence, Dysfunction and Atherosclerosis
Ota, H., Eto, M., Ogawa, S., Iijima, K., Akishita, M., & Ouchi, Y. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.3525 · Cited by 147
SIRT1 modulates MAPK pathways in ischemic–reperfused cardiomyocytes
Becatti, M., Taddei, N., Cecchi, C., Nassi, N., Nassi, P., & Fiorillo, C. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0925-5 · Cited by 148
“treat metabolic disorders characterized by defective Akt signaling [45].”
BackgroundValidation of anti-aging drugs by treating age-related diseases
Blagosklonny, M. V. (2009) · Aging · doi:10.18632/aging.100034 · Cited by 140
“Therefore, more selective activators of SIRT1 undergo clinical trials [3].”
BackgroundYang, Q., Wang, B., Zang, W., Wang, X., Liu, Z., Li, W., & Jia, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070627 · Cited by 139
“Numerous studies show that Res exerts diverse effects in different models in a Sirt1-dependent manner [40,41].”
BackgroundSIRT1 Genetic Variation Is Related to BMI and Risk of Obesity
Zillikens, M. C., van Meurs, J. B. J., Rivadeneira, F., Amin, N., Hofman, A., Oostra, B. A., Sijbrands, E. J. G., Witteman, J. C. M., Pols, H. A. P., van Duijn, C. M., et al. (2009) · Diabetes · doi:10.2337/db09-0536 · Cited by 139
“More research on pharmacology and possible side effects in humans is necessary for this compound as well as for recently developed more potent SIRT1 activators (50).”
BackgroundGene-chip studies of adipogenesis-regulated microRNAs in mouse primary adipocytes and human obesity
Keller, P., Gburcik, V., Petrovic, N., Gallagher, I. J., Nedergaard, J., Cannon, B., & Timmons, J. A. (2011) · BMC Endocrine Disorders · doi:10.1186/1472-6823-11-7 · Cited by 139
“Accordingly, Sirt1 activators improve insulin resistance in ob/ob and diet-induced obese mice, and increase insulin sensitivity in obese, insulin-resistant Zucker rats [49].”
BackgroundSadria, M., & Layton, A. T. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00706-1 · Cited by 154
“[42]).”
Perspectives on translational and therapeutic aspects of SIRT1 in inflammaging and senescence
Yao, H., & Rahman, I. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.06.031 · Cited by 139
Alcaín, F. J., & Villalba, J. M. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902762893 · Cited by 137
“SRT1460 and SRT1720 bind and activate SIRT1 at the same molecular site as RV [84].”
BackgroundXu, Y. X., Nie, L., Yin, Y., Tang, J.-L., Zhou, J., Li, D., & Zhou, S.-W. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.09.028 · Cited by 144
“Therefore, small molecule activators of SIRT1 have attractedmuch attention as promising new therapeutics for the treatment of diabetes and its complications (Milne et al., 2007).”
BackgroundMacronutrients and caloric intake in health and longevity
Solon-Biet, S. M., Mitchell, S. J., de Cabo, R., Raubenheimer, D., Le Couteur, D. G., & Simpson, S. J. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0173 · Cited by 137
“…2015 Society for Endocrinology DOI: 10.1530/JOE-15-0173 Printed in Great Britain activate SIRT1 and delay aging, including resveratrol and SRT2014 (Howitz et al. 2003, Baur et al. 2006, Milne et al. 2007, Mercken et al. 2014, Sinclair & Guarente 2014).”
InfluentialMechanisms and Molecular Probes of Sirtuins
Smith, B. C., Hallows, W. C., & Denu, J. M. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.09.009 · Cited by 136
“More recently, Milne et al. have shown that Sirt1-specific activators, structurally unrelated to resveratrol, could provide novel treatments of type II diabetes (Milne et al., 2007).”
BackgroundWu, T., Liu, Y., Fu, Y., Liu, X., & Zhou, X.-H. (2014) · PubMed · Cited by 140
A high-throughput respirometric assay for mitochondrial biogenesis and toxicity
Beeson, C. C., Beeson, G. C., & Schnellmann, R. G. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.04.040 · Cited by 131
“For example, resveratrol and SRT1720 produce mitochondrial biogenesis and they are being studied for the treatment of type 2 diabetes and aging [23].”
BackgroundCheng, C. Y., Gutierrez, N. M., Marzuki, M., Lu, X., Foreman, T. W., Paleja, B. S., Lee, B. T. K., Balachander, A., Chen, J., Tsenova, L., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aaj1789 · Cited by 142
The Critical Role of SIRT1 in Parkinson’s Disease: Mechanism and Therapeutic Considerations
Li, X., Feng, Y., Wang, X.-X., Truong, D., & Wu, Y.-C. (2020) · Aging and disease · doi:10.14336/ad.2020.0216 · Cited by 134
“Since then, high-throughput screening and medicinal chemistry efforts have identified more than 14,000 STACs from a dozen chemical classes, including plant-derived STACs such as stilbenes (resveratrol), chalcones (butein), and flavones (quercetin) [107] and synthetic STACs including imidazothiazoles (SRT1720) [108], t…”
BackgroundInfluentialHoffmann, E., Wald, J., Lavu, S., Roberts, J., Beaumont, C., Haddad, J., Elliott, P., Westphal, C., & Jacobson, E. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04340.x · Cited by 132
Self-citationSirtuin deacylases: a molecular link between metabolism and immunity
Preyat, N., & Léo, O. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1112557 · Cited by 141
“SRT2104, SRT2183, and SRT2530 [133–135].”
Yun, J., Chien, A., Jialal, I., & Devaraj, S. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.03.012 · Cited by 142
“As one possible mechanism, SIRT1 enhances the activity of the FOXO by their nuclear translocation [22] and probably regulates the gene-specific transcription [24,35,42,44].”
Metabolism, hypoxia and the diabetic heart
Heather, L. C., & Clarke, K. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.01.007 · Cited by 141
Glycomimetics for the inhibition and modulation of lectins
Leusmann, S., Ménová, P., Shanina, E., Titz, A., & Rademacher, C. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00954d · Cited by 142
Lysine deacetylation in ischaemic preconditioning: the role of SIRT1
Nadtochiy, S. M., Redman, E., Rahman, I., & Brookes, P. S. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq287 · Cited by 130
Ølholm, J., Paulsen, S. K., Cullberg, K. B., Richelsen, B., & Pedersen, S. B. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.98 · Cited by 135
Resveratrol Chemosensitizes TNF-β-Induced Survival of 5-FU-Treated Colorectal Cancer Cells
Buhrmann, C., Yazdi, M., Popper, B., Shayan, P., Goel, A., Aggarwal, B. B., & Shakibaei, M. (2018) · Nutrients · doi:10.3390/nu10070888 · Cited by 140
Bruckbauer, A., Zemel, M. B., Thorpe, T., Akula, M. R., Stuckey, A. C., Osborne, D., Martin, E. B., Kennel, S., & Wall, J. S. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-77 · Cited by 128
“Therefore, Sirt1 activators have been suggested as therapeutic targets for insulin resistance, diabetes and metabolic disease [38,39].”
BackgroundKumar, M., Seeger, W., & Voswinckel, R. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0382ps · Cited by 127
“A more potent SIRT1-specific activator than resveratrol has been developed and examined recently as therapy for diabetes (129).”
BackgroundSIRT1 is required for long-term growth of human mesenchymal stem cells
Yuan, H., Zhai, C., Yan, X., Zhao, D., Wang, J., Zeng, Q., Chen, L., Nan, X., He, L., Li, S.-T., et al. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0825-4 · Cited by 129
“In many studies, resveratrol has been considered to be an activator of SIRT1 and has been reported to improve insulin sensitivity, increase mitochondrial content, and prolong survival of mice fed a high-fat, high-calorie diet [25, 26, 32, 33].”
BackgroundComprehensive Survey of Chemical Libraries for Drug Discovery and Chemical Biology: 2007
Dolle, R. E., Bourdonnec, B. L., Goodman, A. J., Morales, G. A., Thomas, C. J., & Zhang, W. (2008) · Journal of Combinatorial Chemistry · doi:10.1021/cc800119z · Cited by 127
Lysine acetylation in obesity, diabetes and metabolic disease
Iyer, A., Fairlie, D. P., & Brown, L. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.99 · Cited by 126
SIRT2-mediated protein deacetylation: An emerging key regulator in brain physiology and pathology
Harting, K., & Knöll, B. (2009) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2009.11.006 · Cited by 135
Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release
Xin, G., Wei, Z., Ji, C., Zheng, H., Gu, J., Ma, L., Huang, W., Morris-Natschke, S. L., Yeh, J.-L., Zhang, R., et al. (2016) · Scientific Reports · doi:10.1038/srep36222 · Cited by 125
Sirtuins and nonalcoholic fatty liver disease
Nassir, F., & Ibdah, J. A. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i46.10084 · Cited by 135
Chen, T., Liu, J., Li, N., Wang, S., Liu, H., Li, J., Zhang, Y., & Bu, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118909 · Cited by 136
“It has been proven that sirtuins are novel therapeutics that inhibit metabolic disorders and combat associated diseases [10,11].”
BackgroundHigh-intensity interval training increases SIRT1 activity in human skeletal muscle
Gurd, B. J., Perry, C. G. R., Heigenhauser, G. J. F., Spriet, L. L., & Bonen, A. (2010) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h10-030 · Cited by 124
“2009) are consistent with results from rodent models in which pharmacological activation of SIRT1 increased mitochondrial content and function (Lagouge et al. 2006; Milne et al. 2007; Feige et al. 2008).”
ResultPagel-Langenickel, I., Bao, J., Joseph, J. J., Schwartz, D. R., Mantell, B. S., Xu, X., Raghavachari, N., & Sack, M. N. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800842200 · Cited by 124
Roles of AMP-Activated Protein Kinase in Diabetes-Induced Retinal Inflammation
Kubota, S., Ozawa, Y., Kurihara, T., Sasaki, M., Yuki, K., Miyake, S., Noda, K., Ishida, S., & Tsubota, K. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8041 · Cited by 127
“Preclinical data revealed that resveratrol application in mice with type 2 diabetes led to significant amelioration of insulin sensitivity and blood glucose levels.(40) Importantly, our systemic data (Table 1) showed that the current dose and duration of resveratrol did not alter blood glucose, suggesting that the pre…”
ResultKubota, S., Kurihara, T., Ebinuma, M., Kubota, M., Yuki, K., Sasaki, M., Noda, K., Ozawa, Y., Oike, Y., Ishida, S., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100098 · Cited by 133
“Indeed, administration of resveratrol extended life spans of yeast,(7) Caenorhabditis elegans,(8) Drosophila melanogaster,(8,9) short-lived fish Nothobranchius furzeri(10) and mice fed with a high-fat diet.(11) We have shown that resveratrol is anti-inflammatory in the eye.”
BackgroundCentral Administration of Resveratrol Improves Diet-Induced Diabetes
Ramadori, G., Gautron, L., Fujikawa, T., Vianna, C. R., Elmquist, J. K., & Coppari, R. (2009) · Endocrinology · doi:10.1210/en.2009-0528 · Cited by 123
“hyperglycemia, hyperinsulinemia, glucose intolerance, enhanced hepatic glucose production) (4, 5, 9).”
BackgroundLi, K., Zhai, M., Jiang, L., Song, F., Zhang, B., Li, J., Li, H., Li, B., Xia, L., Xu, L. L., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/6746907 · Cited by 129
Discovery of Imidazo[1,2- b ]thiazole Derivatives as Novel SIRT1 Activators
Vu, C. B., Bemis, J. E., Disch, J. S., Ng, P. Y., Nunes, J. J., Milne, J. C., Carney, D. P., Lynch, A. V., Smith, J. J., Lavu, S., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8012954 · Cited by 122
Self-citationNadtochiy, S. M., & Redman, E. K. (2011) · Nutrition · doi:10.1016/j.nut.2010.12.006 · Cited by 122
“It was demonstrated that the synthetic SIRT1 activator SRT1720 was 1000 times more potent than resveratrol and could suppress aged-related disturbances in model animals [162].”
BackgroundQin, F., Siwik, D. A., Luptak, I., Hou, X., Wang, L., Higuchi, A., Weisbrod, R. M., Ouchi, N., Tu, V. H., Calamaras, T. D., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.067801 · Cited by 122
Wang, L., Teng, R., Di, L., Rogers, H., Wu, H., Kopp, J. B., & Noguchi, C. T. (2013) · Diabetes · doi:10.2337/db13-0518 · Cited by 122
“Activation of Sirt1 can improve metabolic dysregulation, insulin resistance, and glucose intolerance by enhanced b-oxidation of free fatty acids and promotes mitochondrial biogenesis in obese mice in an NAD+ dependent way (28,29,46,47).”
Albani, D., Polito, L., & Forloni, G. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1215 · Cited by 121
SIRT1 metabolic actions: Integrating recent advances from mouse models
Boutant, M., & Cantó, C. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.10.006 · Cited by 121
“A more recent screen for other possible small molecular SIRT1 agonists led to the identification of a second batch of compounds, among which the best characterized is SRT1720 [97].”
BackgroundInfluentialImpaired SIRT1 nucleocytoplasmic shuttling in the senescent heart during ischemic stress
Tong, C., Morrison, A., Mattison, S., Qian, S., Bryniarski, M., Rankin, B., Wang, J., Thomas, D. P., & Li, J. (2013) · The FASEB Journal · doi:10.1096/fj.12-216473 · Cited by 121
The Current State of NAD+‐Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic Targets
Schiedel, M., Robaa, D., Rumpf, T., Sippl, W., & Jung, M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21436 · Cited by 137
SIRT1 as a therapeutic target in inflammaging of the pulmonary disease
Rahman, I., Kinnula, V. L., Gorbunova, V., & Yao, H. (2012) · Preventive Medicine · doi:10.1016/j.ypmed.2011.11.014 · Cited by 120
“SRT1720 has been reported to be 800–1000-fold more effective than resveratrol in activating SIRT1 (Milne et al., 2007).”
BackgroundSirt1 Is Required for Resveratrol-Mediated Chemopreventive Effects in Colorectal Cancer Cells
Buhrmann, C., Shayan, P., Popper, B., Goel, A., & Shakibaei, M. (2016) · Nutrients · doi:10.3390/nu8030145 · Cited by 123
Therapeutic role of sirtuins in neurodegenerative disease
Outeiro, T. F., Marques, O., & Kazantsev, A. G. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.02.010 · Cited by 139
Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography
Davies, D. R., Mamat, B., Magnusson, O. T., Christensen, J., Haraldsson, M. H., Mishra, R., Pease, B., Hansen, E., Singh, J., Zembower, D., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900259h · Cited by 119
Mechanism of p300 Specific Histone Acetyltransferase Inhibition by Small Molecules
Arif, M., Pradhan, S. K., G R, T., Vedamurthy, B. M., Agrawal, S., Dasgupta, D., & Kundu, T. K. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800657z · Cited by 118
Sirtuins and Their Relevance to the Kidney
Hao, C.-M., & Haase, V. H. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010046 · Cited by 118
TOR signaling never gets old: Aging, longevity and TORC1 activity
Evans, D. S., Kapahi, P., Hsueh, W.-C., & Kockel, L. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2010.04.001 · Cited by 117
Joseph, A.-M., Joanisse, D. R., Baillot, R. G., & Hood, D. A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/642038 · Cited by 117
“[153], obese animals treated with small SIRT1 activator molecules were shown to display enhanced mitochondrial function and improved insulin sensitivity, indicating the potential use of these drugs in the treatment of type 2 diabetes.”
BackgroundSIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis
Zainabadi, K., Liu, C. J., Caldwell, A. L. M., & Guarente, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185236 · Cited by 119
Cano, R., Pérez, J., Dávila, L., Ortega, Á., Gómez, Y., Valero-Cedeño, N., Parra, H., Manzano, A., Véliz-Castro, T. I., Albornoz, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094807 · Cited by 131
Tsunemi, T., & La Spada, A. R. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.10.004 · Cited by 117
Kim, Y. J., Hwang, S. H., Lee, S. Y., Shin, K. K., Cho, H. H., Bae, Y. C., & Jung, J. S. (2012) · Stem Cells and Development · doi:10.1089/scd.2011.0429 · Cited by 116
“SIRT1 plays an important role in regulating pathogenesis of chronic conditions, including diabetes and aging-related disease [31].”
Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity
Dal-Pan, A., Blanc, S., & Aujard, F. (2010) · BMC Physiology · doi:10.1186/1472-6793-10-11 · Cited by 116
“Likewise, resveratrol and assimilated SIRT1 activators have been proposed as potential treatments for type 2 diabetes in mice models [14,12,27,28].”
Identification of a SIRT1 Mutation in a Family with Type 1 Diabetes
Biason-Lauber, A., Böni-Schnetzler, M., Hubbard, B. P., Bouzakri, K., Brunner, A., Cavelti-Weder, C., Keller, C., Meyer-Böni, M., Meier, D. T., Brorsson, C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.02.001 · Cited by 116
“Early studies in budding yeast helped to identify sirtuin deacetylases as key enzymes that coordinate the organism’s response to calorie intake and the regulation of life span (Banks et al., 2008; Cantó et al., 2009; Haigis and Guarente, 2006; Milne et al., 2007; Westphal et al., 2007; Yoshizaki et al., 2009a).”
Self-citationThe role of ADAM17 in metabolic inflammation
Menghini, R., Fiorentino, L., Casagrande, V., Lauro, R., & Federici, M. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.024 · Cited by 114
“Alternatively, drugs used to improve Sirtuins such as Resveratrol or the proposed indirect SirT1 activators [66]might decrease ADAM17 indirectly through increased TIMP3 expression, which could also lead to other potentially beneficial TIMP3 effects such as inhibition of MMP2 and MMP9 [67]or VEGR2 [45].”
BackgroundSong, S. B., Jang, S.-Y., Kang, H. T., Wei, B., Jeoun, U.-W., Yoon, G. S., & Hwang, E. S. (2017) · Molecules and Cells · doi:10.14348/molcells.2017.0081 · Cited by 114
“(EC50 reported by Milne et al. (2007) was 1.16 M and >300 M for SIRT1 and SIRT3, respectively.)”
InfluentialMuñoz-Najar, U., & Sedivy, J. M. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3250 · Cited by 114
“Especially interesting is the data showing that resveratrol treatment of mice subjected to a prolonged high-fat diet increases lifespan, apparently mimicking the well-established contribution of dietary CR to longevity (8, 24, 147).”
Potential Modulation of Sirtuins by Oxidative Stress
Santos, L., Escande, C., & Denicola, A. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9831825 · Cited by 114
“Since then, many molecular mechanisms have been proposed for SIRT1 activation by resveratrol in vivo, including direct SIRT1 activation [97, 99], activation of the AMPKSIRT1 axis with NAD levels linking AMPK activation to SIRT1 activation [100], activation of the AMPK-SIRT1 axis through SIRT1 phosphorylation and disso…”
BackgroundDas, S. K., Wang, W., Zhabyeyev, P., Basu, R., McLean, B. A., Dong, F., Parajuli, N., DesAulniers, J., Patel, V. B., Hajjar, R. J., et al. (2015) · Scientific Reports · doi:10.1038/srep18132 · Cited by 120
Qin, Z., Fang, X., Sun, W., Ma, Z., Dai, T., Wang, S., Zong, Z., Huang, H., Ru, H., Lu, H., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01269-0 · Cited by 121
Dietary Interventions to Extend Life Span and Health Span Based on Calorie Restriction
Minor, R. K., Allard, J. S., Younts, C. M., Ward, T. M., & de Cabo, R. (2010) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glq042 · Cited by 113
Wang, C., Wheeler, C. T., Alberico, T., Sun, X., Seeberger, J., Laslo, M., Spangler, E. L., Kern, B., de Cabo, R., & Zou, S. (2011) · AGE · doi:10.1007/s11357-011-9332-3 · Cited by 126
Molecular insights into the premature aging disease progeria
Vidak, S., & Foisner, R. (2016) · Histochemistry and Cell Biology · doi:10.1007/s00418-016-1411-1 · Cited by 112
“Resveratrol treatment was previously shown to increase life span in yeast, worms, and flies and to enhance health span in rodents (Baur et al. 2006; Howitz et al. 2003; Milne et al. 2007; Wood et al. 2004).”
BackgroundSirt1 Promotes Axonogenesis by Deacetylation of Akt and Inactivation of GSK3
Li, X., Chen, C., Tu, Y., Sun, H., Zhao, M., Cheng, S., Qu, Y., & Zhang, S. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8437-3 · Cited by 123
“Sirt1 regulates many of the same cellular processes regulated by Akt [16], and Sirt1 activators have been used to treat metabolic disorders characterized by defective Akt signaling [19], indicating an underlying association of Sirt1 and Akt.”
BackgroundAvila, C., Huang, R., Stevens, M., Aponte, A. M., Tripodi, D., Kim, K., & Sack, M. N. (2011) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0031-1285833 · Cited by 124
Peptide Switch Is Essential for Sirt1 Deacetylase Activity
Kang, H., Suh, J.-Y., Jung, Y.-S., Jung, J.-W., Kim, M. K., & Chung, J. H. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.07.038 · Cited by 111
“Compounds such as resveratrol and SRT1720 have been reported to activate Sirt1 (Howitz et al., 2003; Milne et al., 2007).”
Resveratrol serves as a protein-substrate interaction stabilizer in human SIRT1 activation
Hou, X., Rooklin, D., Fang, H., & Zhang, Y. (2016) · Scientific Reports · doi:10.1038/srep38186 · Cited by 111
Henstridge, D. C., Whitham, M., & Febbraio, M. A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.08.003 · Cited by 111
“Activation of key proteins and/or pathways involving AMP-activated protein kinase (AMPK) [67], Peroxisome proliferator-activated receptor delta (PPARd) [68], sirtuin 1 (SIRT)1 [69] and carnitine palmitoyltransferase-1 (CPT1) [70], increase fatty acid oxidation (FAO).”
BackgroundMetabolic effects of resveratrol: Addressing the controversies
Bitterman, J. L., & Chung, J. H. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1808-8 · Cited by 109
“Using a proposed Sirt1 activator, SRT1720, many of these same effects have been seen in mice fed a high fat diet including improved glucose tolerance, insulin sensitivity, mitochondrial content, and lifespan [108, 109].”
Natural Bioactive Compounds Useful in Clinical Management of Metabolic Syndrome
Noce, A., Lauro, M. D., Daniele, F. D., Zaitseva, A. P., Marrone, G., Borboni, P., & Daniele, N. D. (2021) · Nutrients · doi:10.3390/nu13020630 · Cited by 126
“The latter activation induces an improvement of insulin sensitivity and glycemic homeostasis [182,183].”
BackgroundKim, Y. H., Kim, Y. S., Roh, G. S., Choi, W. S., & Cho, G. J. (2012) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2011.02243.x · Cited by 109
“2012: 90: e31–e37 ª 2011 The Authors Acta Ophthalmologica ª 2011 Acta Ophthalmologica Scandinavica Foundation doi: 10.1111/j.1755-3768.2011.02243.x e31 of insulin sensitivity (Sharma et al. 2006; Milne et al. 2007; Thirunavukkarasu et al. 2007).”
BackgroundInfluentialInduction of Hypothalamic Sirt1 Leads to Cessation of Feeding via Agouti-Related Peptide
Sasaki, T., Kim, H.-J., Kobayashi, M., Kitamura, Y.-I., Yokota-Hashimoto, H., Shiuchi, T., Minokoshi, Y., & Kitamura, T. (2010) · Endocrinology · doi:10.1210/en.2009-1319 · Cited by 108
“and specific activator of Sirt1, improves diabetes in rodents (10).”
BackgroundSirtuin-1 regulation of mammalian metabolism
Gillum, M. P., Erion, D. M., & Shulman, G. I. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.005 · Cited by 108
Loss of SIRT1 in diabetes accelerates DNA damage-induced vascular calcification
Bartoli‐Leonard, F., Wilkinson, F. L., Schiro, A., Serracino‐Inglott, F., Alexander, M. Y., & Weston, R. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa134 · Cited by 112
The role of SIRT1 in ocular aging
Mimura, T., Kaji, Y., Noma, H., Funatsu, H., & Okamoto, S. (2013) · Experimental Eye Research · doi:10.1016/j.exer.2013.07.017 · Cited by 122
Costa, C. D. S., Hammes, T. O., Rohden, F., Margis, R., Bortolotto, J. W., Padoin, A. V., Mottin, C. C., & Guaragna, R. M. V. D. C. (2009) · Obesity Surgery · doi:10.1007/s11695-009-0052-z · Cited by 114
Obesity: Pathophysiology and Clinical Management
Gurevich-Panigrahi, T., Panigrahi, S., Wiecheć, E., & Łoś, M. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787315568 · Cited by 134
“Moreover, resveratrol intake protects against radiation [109], development of c ancer, c ardiovascular di sorders [ 110-112] as well as is utilized in treatment of metabolic disorders such as diabetes 2 [ 113].”
AMP-Activated Protein Kinase and Metabolic Control
Viollet, B., & Andréelli, F. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_13 · Cited by 121
Fancd2 −/− mice have hematopoietic defects that can be partially corrected by resveratrol
Zhang, Q., Loza, L. I. M., Eaton, L., Duncan, A. W., Goldman, D. C., Anur, P., Watanabe‐Smith, K., Rathbun, R. K., Fleming, W., Bagby, G. C., et al. (2010) · Blood · doi:10.1182/blood-2010-04-278226 · Cited by 114
Human Sirtuin Regulators: The “Success” Stories
Curry, A. M., White, D. S., Donu, D., & Cen, Y. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.752117 · Cited by 116
“5 = 46.2 µM and a maximum activation of 2-fold (Milne et al., 2007).”
BackgroundInfluentialSIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells
Khan, R. S., Fonseca-Kelly, Z., Callinan, C., Zuo, L., Sachdeva, M. M., & Shindler, K. S. (2012) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2012.00063 · Cited by 105
“…plant polyphenol (Siemann and Creasey, 1992; Dong, 2003), and SRTAW04, a compound that activates SIRT1 at an order of magnitude lower concentration, similar to other SIRT1 activators (Milne et al., 2007), both significantly reduce loss of RGC-5 cells in response to several different stressors.”
BackgroundPharmacological modulation of circadian rhythms by synthetic activators of the deacetylase SIRT1
Bellet, M. M., Nakahata, Y., Boudjelal, M., Watts, E., Mossakowska, D. E., Edwards, K. A., Cervantes, M., Astarita, G., Loh, C., Ellis, J. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214266110 · Cited by 104
“To do this approach, we activated both endogenous and overexpressed SIRT1 with different concentrations of the previously described STAC SRT2183 (11) or with NAD.”
BackgroundMethodResultInfluentialKizhakekuttu, T. J., Wang, J., Dharmashankar, K., Ying, R., Gutterman, D. D., Vita, J. A., & Widlansky, M. E. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.256024 · Cited by 105
“of NO bioavailability leads to excessive mitochondrial superoxide production.(35) Our data extend these findings to”
ResultSIRT1 protects against cigarette smoke-induced lung oxidative stress via a FOXO3-dependent mechanism
Yao, H., Sundar, I. K., Ahmad, T., Lerner, C., Gerloff, J., Friedman, A. E., Phipps, R. P., Sime, P. J., McBurney, M. W., Guarente, L., et al. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00323.2013 · Cited by 104
“SRT1720 [100 mg/kg, 95% pure by C-(13) nuclear magnetic resonance and liquid chromatography–mass spectrometry (LC-MS), synthesized from Life Chemicals] was administered through oral gavage 1 h before CS exposure daily for 3 days (43, 66).”
MethodSIRT1 mRNA expression may be associated with energy expenditure and insulin sensitivity
Rutanen, J., Yaluri, N., Modi, S., Pihlajamäki, J., Vänttinen, M., Itkonen, P., Kainulainen, S., Yamamoto, H., Lagouge, M., Sinclair, D. A., et al. (2010) · Diabetes · doi:10.2337/db09-1191 · Cited by 104
“Small molecule activators of SIRT1, that are structurally unrelated to resveratrol, have also been shown to improve insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity (6).”
BackgroundSelf-citationMitochondrial Metabolic Reprogramming Induced by Calorie Restriction
Martin-Montalvo, A., & de Cabo, R. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4866 · Cited by 104
“SRT 1720 and SRT501 Diabetes, longevity(65, 66)”
Sirtuins in vascular diseases: Emerging roles and therapeutic potential
D’Onofrio, N., Vitiello, M., Casale, R., Servillo, L., Giovane, A., & Balestrieri, M. L. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.03.001 · Cited by 111
“In mice model, the compound SRT1720, a potent SIRT1 activator [6], reduces glucose levels and liver triglyceride content and recover mitochondrial functions after acute oxidant injury [120–122].”
BackgroundInfluentialPannek, M., Simic, Z., Fuszard, M., Meleshin, M., Rotili, D., Mai, A., Schutkowski, M., & Steegborn, C. (2017) · Nature Communications · doi:10.1038/s41467-017-01701-2 · Cited by 103
Glycolytic inhibition as a strategy for developing calorie restriction mimetics
Ingram, D. K., & Roth, G. S. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.12.001 · Cited by 113
“…as the great flurry of activity surrounding research in manipulation of sirtuins as a strategy for developing CRM (Baur, 2010; Baur et al., 2006; Chen and Guarente, 2007; Howitz et al., 2003; Kaeberlein, 2010; Kume et al., 2010; Milne et al., 2007; Pearson et al., 2008;Wood et al., 2004).”
Delipidating effect of resveratrol metabolites in 3 T 3‐L 1 adipocytes
Lasa, A., Churruca, I., Eseberri, I., Andrés‐Lacueva, C., & Portillo, M. P. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100772 · Cited by 103
Kang, W., Hong, H. J., Guan, J., Kim, D. G., Yang, E.-J., Koh, G., Park, D.-B., Han, C. H., Lee, Y. J., & Lee, D.-H. (2011) · Metabolism · doi:10.1016/j.metabol.2011.08.003 · Cited by 109
“Furthermore, experimental evidences revealed that high doses of RSV or its analogues caused a significant improvement in insulin sensitivity in variousmurine models with insulin resistance [3-5,17,18].”
BackgroundAntidiabetic Effects of Resveratrol: The Way Forward in Its Clinical Utility
Oyenihi, O. R., Oyenihi, A. B., Adeyanju, A. A., & Oguntibeju, O. O. (2016) · Journal of Diabetes Research · doi:10.1155/2016/9737483 · Cited by 123
“SIRT1 activity and expression were decreased significantly in in vitro and in vivo experimental models of DM [75, 76].”
Background
Metadata
- Authors
- Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L., Boss, O., Perni, R. B., Vu, C. B., Bemis, J. E., Xie, R., Disch, J. S., Ng, P. Y., Nunes, J. J., Lynch, A. V., Yang, H., Galonek, H., Israelian, K., Choy, W., Iffland, A., Lavu, S., Medvedik, O., Sinclair, D. A., Olefsky, J. M., Jirousek, M. R., Elliott, P. J., & Westphal, C. H.
- Affiliations
- University of California San Diego (US)
- Harvard University (US)
- Corresponding author
- Westphal, Christoph H.
- ORCID
- Venue
- Nature
- Published
- 2007-11-29
- Volume
- 450
- Issue
- 7170
- Pages
- 712-716
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2753457
- OpenAlex
- W2116350182
- Cited by
- 1,707
- References
- 27
- Citations by year
- 2026: 38 · 2025: 43 · 2024: 55 · 2023: 55 · 2022: 68 · 2021: 100 · 2020: 80 · 2019: 75 · 2018: 82 · 2017: 69 · 2016: 92 · 2015: 89 · 2014: 110 · 2013: 119 · 2012: 126
- FWCI
- 55.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (P01AG027916, R01AG028730, R01AG019719)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- SIRT1, small molecule activators, type 2 diabetes, insulin resistance, caloric restriction mimetics, resveratrol, NAD+-dependent deacetylase, allosteric site, glucose homeostasis, mitochondrial function, obesity, aging, drug screening
- MeSH terms
- Resveratrol, Acetylation, Allosteric Site, Animals, Blood Glucose, Cell Line, Diabetes Mellitus, Type 2, Dietary Fats, Disease Models, Animal, Drosophila melanogaster, Heterocyclic Compounds, 4 or More Rings, Humans, Insulin, Male, Mitochondria, Rats, Zucker, Stilbenes, Rats, Sprague-Dawley, Catalytic Domain, Caloric Restriction, Sirtuins, Mice, Rats, Sirtuin 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.